Citation & Authors
Mayo Clin Proc. 2026;101(6):909–919.
ABSTRACT · RESEARCH SUMMARY
Research summary
The study matched 24,510 pairs of new GLP-1 and DPP-4 drug users without CKD at baseline. The GLP-1 group had a lower risk of the composite kidney outcome (HR 0.85; 95% CI 0.82–0.87), as well as fewer cases of incident CKD, dialysis, acute kidney injury, major cardiac events, and death. The results support potential cardiorenal benefits but remain observational.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
Key findings
Matching yielded 24,510 pairs. Compared with DPP-4 inhibitors, GLP-1 receptor agonists were associated with lower risks of incident chronic kidney disease (HR 0.85; 95% CI 0.82–0.88) and dialysis (HR 0.53; 95% CI 0.43–0.64).
These findings come from target trial emulation using observational data, and residual confounding may remain. Participants did not have chronic kidney disease at baseline; the results should not be directly extrapolated to all patients with kidney disease.
